TCL-SPION-enhanced MRI for the Detection of Lymph Node Metastasis in Murine Experimental Model

Academic Radiology

Volumn 18, Issue 4, 2011, Pages 504-511

  Lim, Se Woong ^a   Kim, Hye Won ^a   Jun, Hong Yeoung ^a   Park, Seong Hoon ^a   Yoon, Kwon Ha ^a   Kim, Hun Soo ^a   Jon, Sangyong ^b   Yu, Mi Kyung ^b   Juhng, Seon Kwan ^a  

^a Wonkwang University School of Medicine   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Contrast media; Iron; Lymph node; Magnetic resonance; Metastases; MR

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; THERMALLY CROSS LINKED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CROSS LINKING; DIAGNOSTIC IMAGING; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; LYMPH NODE METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; DEXTRANS; DISEASE MODELS, ANIMAL; HUMANS; IMAGE ENHANCEMENT; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MELANOMA; MICE; MICE, INBRED C57BL;

EID: 79952183324     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.10.017     Document Type: Article

References (33)

1. Dowlatshahi K., Fan M., Snider H.C., et al. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997, 80:1188-1197.
2. Herrera-Ornelas L., Justiniano J., Castillo N., et al. Metastases in small lymph nodes from colon cancer. Arch Surg 1987, 122:1253-1256.
3. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph node metastases in prostate cancer. N Engl J Med 2003, 348:2491-2499.
4. Mack M.G., Balzer J.O., Straub R., et al. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002, 222:239-244.
5. Harisinghani M.G., Saini S., Hahn P.F., et al. MR imaging of lymph nodes in patients with primary abdominal and pelvic malignancies using ultrasmall superparamagnetic iron oxide (Combidex). Acad Radiol 1998, 5:S167-S169.
6. Raynal I., Prigent P., Peyramaure S., et al. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004, 39:56-63.
7. McLachlan S.J., Morris M.R., Lucas M.A., et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994, 43:301-307.
8. Wunderbaldinger P., Josephson L., Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002, 9:S304-S306.
9. Lee H., Yu M.K., Park S., et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc 2007, 129:12739-12745.
10. Lee H., Lee E., Kim D.K., et al. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc 2006, 128:7383-7389.
11. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
12. Mikhaylova M., Kim D.K., Bobraysheva N., et al. Superparamagnetism of magnetite nanoparticles: dependence on surface modification. Langmuir 2004, 20:2472-2477.
13. Hart I.R., Fidler I.J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40:2281-2287.
14. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975, 35:218-224.
15. Koh D.M., Brown G., Temple L., et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings. Radiology 2004, 231:91-99.
16. Wunderbaldinger P., Josephson L., Bremer C. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Mag Reson Med 2002, 47:292-297.
17. Memarsadeghi M., Riedl C.C., Kaneider A., et al. Axillary lymph node metastases in patients with breast carcinomas: assessment with nonenhanced versus USPIO-enhanced MR imaging. Radiology 2006, 241:367-377.
18. Bellin M.F., Roy C., Kinkel K., et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 1998, 207:799-808.
19. Corot C., Robert P., Idée L.M., et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504.
20. Kohler N., Fryxell G.E., Zhang M. A bifunctional poly (ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc 2004, 126:7206-7211.
21. Yu M.K., Jeong Y.Y., Park J., et al. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed 2008, 47:5362-5365.
22. Kim D.K., Mikhaylova M., Wang F.H., et al. Starch-coated superparamagnetic nanoparticles as MR contrast agents. Chem Mat 2003, 15:4343-4351.
23. Wang Y.X., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physiochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
24. Cho W.S., Cho M., Kim S.R., et al. Pulmonary toxicity and kinetic study of Cy5.5-conjugated superparamagnetic iron oxide nanoparticles by optical imaging. Toxicol Appl Pharmacol 2009, 239:106-115.
25. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 1990, 175:494-498.
26. Garlick D.G., Renkin E.M. Transport of large molecules from plasma to intestitial fluid and lymph in dogs. Am J Physiol 1970, 219:1595-1605.
27. Ogisho Y., Matsuoka O. Time dependent changes of microscopic localization of intravenously administered colloidal carbon particles in mouse lymph nodes. J Toxicol Sci 1983, 8:291-300.
28. Lind K., Kresse M., Debus N.P., et al. A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphography: comparison of hysicochemical properties and the in vivo behaviour. J Drug Target 2002, 10:221-230.
29. Wagner S., Pfefferer D., Ebert W., et al. Intravenous MR lymphography with superparamagnetic iron oxide particles: experimental studies in rats and rabbits. Eur Radiol 1995, 5:640-646.
30. Bourrinet P., Bengele H.H., Bonnemain B., et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10 an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006, 413:313-324.
31. Wagner S., Schnorr J., Pilgrimm H., et al. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002, 37:167-177.
32. Weinreb J.C., Brateman L., Babcock E.E., et al. Chemical shift artifact in clinical magnetic resonance images at 0.35 T. AJR Am J Roentgenol 1985, 145:183-185.
33. Frayne R., Goodyear B.G., Dickhoff P., et al. Magnetic resonance imaging at 3.0 tesla: challenges and advantages in clinical neurological imaging. Invest Radiol 2003, 38:385-402.